Mylan (NSDQ:MYL) today announced the launch of its Wixela Inhub product, a generic for GlaxoSmithKline‘s (NYSE:GSK) Advair Diskus device, for people with asthma or chronic obstructive pulmonary disease.
The company touted that its device’s list price is 70% less than Advair Diskus and 67% less than GSK’s generic.
The wholesale acquisition costs for Mylan’s Wixela Inhub devices are $93.71 for the 100mcg/50mcg strength, $116.44 for the 250mcg/50mcg strength and $153.14 for the 500mcg/50mcg strength.
“We’ve had numerous discussions with customers about the need for a unique launch strategy for the first substitutable generic of Advair Diskus that increases affordability to all in our healthcare system,” chief commercial officer Tony Mauro said in prepared remarks.
“We trust that by launching Wixela Inhub at a significantly discounted list price, we will demonstrate the savings that generics can deliver for patients through reduced out-of-pocket costs, as well as the U.S. healthcare system overall,” Mauro added.
Mylan won FDA approval for the Advair generic in January.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.